Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 1,625 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer Genetics Clear all

Conditions: Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Mass, Primary Peritoneal Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions: Laboratory Biomarker Analysis, BMN 673; Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 6
States / cities: Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more

Conditions: Solid Tumors, Breast Cancer, Cowden Syndrome
Interventions: BGT226; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 4
States / cities: Boston, Massachusetts • Las Vegas, Nevada • San Antonio, Texas

Conditions: Breast Cancer
Interventions: Automated program (ChatBot), Genetics counselor, BCGCKQ Survey, Satisfaction Survey, Genetic testing; Genetic · Other · Device
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Kidney Cancer, Leukemia, Lymphoma, Myelodysplastic Syndromes, Neuroblastoma, Sarcoma
Interventions: filgrastim, allogeneic bone marrow transplantation; Biological · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 2
States / cities: Nashville, Tennessee • Seattle, Washington

Conditions: Neurofibromatosis 1, Nerve Sheath Neoplasms
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 120 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2035
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-Hodgkin Lymphoma, Lymphoma Non-Hodgkin, B-cell Lymphoma, Immune Dysregulation
Interventions: Not listed
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 4 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Bethesda, Maryland • Portsmouth, Virginia

Conditions: Breast Cancer
Interventions: Video and Booklet, Factsheet; Behavioral
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer, Ovarian Cancer
Interventions: Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 156 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neurofibromatosis Type 1
Interventions: Not listed
Lead sponsor: John Jay High School; Other
Eligibility: 14 Years to 17 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Cross River, New York

Conditions: Breast Cancer, Benign Breast Disease
Interventions: Sample collection; Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 810 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Tuberous Sclerosis, Neurofibromatoses, Angiofibroma, Neurofibroma
Interventions: Skincerity, Skincerity plus sirolimus/rapamycin, Skinercity plus sirolimus/rapamycin; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 13 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer
Interventions: CUE-102; Drug
Lead sponsor: Cue Biopharma; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 15
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 12 more

Conditions: Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: oblimersen sodium, docetaxel; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 25 Years and older · Female only
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Colorectal Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer, Endometrial Cancer, History of Cancer
Interventions: Publicly available genetic testing resources, Virtual genetics navigator, Motivational interviewing (MI); Other · Behavioral
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 793 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Eyelid Diseases, Ptosis, Eyelid, Blepharoptosis, Dermatochalasis, Ectropion, Entropion, Eyelid Tumor, Skin Cancer, Eyelid, Floppy Eyelid Syndrome
Interventions: Telemedicine follow-up; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Non-cancer Affected Volunteers
Interventions: Saliva or Blood samples; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 60 Years and older
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Thoracic Cancers, Malignant Pleural Mesotheliomas NOS, Lung Cancer NOS, Esophageal Cancers NOS, Cancers of Non Thoracic Origin With Metastases to the Lungs or Pleura, Thoracic Malignancies
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 120 Years
Enrollment: 1,559 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Mild Autonomous Cortisol Secretion, Autonomous Cortisol Secretion (ACS)
Interventions: Osilodrostat 1 MG; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pancreatic Cancer
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms, HER2 Negative Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Gallbladder Carcinoma, Adenoid Cystic Carcinoma
Interventions: Felmetatug Vedotin, Pembrolizumab; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 22
States / cities: Aurora, Colorado • Denver, Colorado • Celebration, Florida + 9 more

Conditions: Hereditary Breast and Ovarian Cancer Syndrome, Osteoporosis, Ovarian Carcinoma
Interventions: Laboratory Biomarker Analysis, Zoledronic Acid; Other · Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 95
States / cities: Scottsdale, Arizona • Tucson, Arizona • Burbank, California + 76 more

Conditions: Dysplastic Nevus Syndrome
Interventions: 20% betulinic acid ointment, BA; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Head and Neck Neoplasms
Interventions: Not listed
Lead sponsor: Montefiore Medical Center; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2030
U.S. locations: 1
States / cities: The Bronx, New York

Search by objective public record fields.

Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer

Effectiveness of AI Genetic Counseling Program vs In-person Genetic Counseling in Breast Cancer

Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease

Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)

Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma

Genetic Counseling for Breast Cancer Survivors (GC for BC)

Attitudes About Childbearing And Fertility With Inherited Breast And Ovarian Cancer Syndromes (HBOC)

How Neurofibromatosis Type 1 (NF1) Affects Schoolwork and Self-Esteem

Johns Hopkins Breast Cancer Program Longitudinal Repository

Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)

A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

Chemotherapy in Treating Patients With Solid Tumors

Adherence to Intensive Surveillance for Hereditary Breast Cancer

Michigan Genetic Hereditary Testing (MiGHT)

Telemedicine Follow-up for Routine, Low-Risk Oculoplastic Surgery

Ascertainment of Saliva or Blood Samples For Genetic Epidemiology Studies of Cancer and Aging

Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining

Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)

Pancreatic Intraepithelial Neoplasia (PanIN) and the Association With Recurrence of Pancreatic Adenocarcinoma

A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries

Evaluation of 20% Betulinic Acid Ointment for Treatment of Dysplastic Nevi (Moderate to Severe Dysplasia)

Molecular and Genomic Profiling of Head and Neck Tumors